Plain-English translation of NCT06940297 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a medication that stops cancer cells from multiplying—combined with a natural plant compound called can improve the results of CAR-T cell therapy for multiple myeloma that has returned or stopped responding to standard treatment. CAR-T therapy is a personalized cancer treatment where your own immune cells are taken out, modified in the lab to recognize and attack your cancer, and then returned to your body. The hope is that adding these two medications will make the treatment work even better.
Multiple myeloma is a serious blood cancer, and some patients' cancers stop responding to standard treatments. Researchers believe that this medication and the plant compound may help boost the immune system's ability to fight back against the cancer cells that remain.
You likely qualify if…
You likely don't qualify if…
You will start the medication by mouth for two days, then receive two chemotherapy drugs by IV over three days to prepare your body. On day zero, you will receive your CAR-T cells by infusion. After that, you will take the medications again on specific days (around days 28, 29, 58, 59, 88, and 89). Throughout the study, you will have CT or PET scans, blood draws, and bone marrow biopsies to monitor how well the treatment is working. The study team will closely watch for side effects and track your response to treatment over time.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States